The Drug Enforcement Administration (DEA) posted a notice on August 4 indicating that it will consider establishing a special registration process to allow providers to write prescriptions for certain controlled substances without first conducting in-person visits. The notice included information on in-person public listening sessions to gather more information on September 12 and 13.

The notice follows a May 9 temporary rule to extend telemedicine flexibilities that were in place during the COVID Public Health Emergency for the prescription of controlled medications through November 11, 2023.  LeadingAge submitted comments on the DEA’s March 1 proposed rule on telemedicine prescribing of controlled substances and will continue to monitor developments on this topic.